NexGel, Inc. (NXGL)

Several events have impacted NexGel's stock over the past six months. Q2 2025 earnings showed a revenue increase, but the stock historically declines post-report. A registered direct offering and private placement occurred, potentially causing short-term volatility. Q3 2025 revenue was flat, but the adjusted EBITDA loss narrowed. The company announced a spin-off of its drug delivery program into NexGelRx. The stock's 52-week range was $1.18 to $3.66, and as of February 5, 2026, it was priced at $1.22, reflecting a year-to-date decrease of 21.1% and underperformance compared to the US Medical Equipment industry and the broader US Market.

NexGel anticipates seasonal improvements in consumer product sales during the holiday seasons (Q3 and Q4). Demand for consumer-branded products like MedaGel, Kenkoderm, and Silly George is expected to increase during these periods. Q3 2024 marked the first full quarter of revenue contribution from the Silly George brand, with optimism for its holiday season performance.

NexGel, Inc. is a materials science company focused on advanced polymer formulations, specifically high-water-content hydrogels. It operates in the medical device industry, targeting wound care, diagnostics, drug delivery, and cosmetics. The company uses contract manufacturing and sells branded products directly to consumers. Key products include hydrogel technology like Arctic5, Arctic10, Synapse, and Mother Earth, healthcare applications such as wound dressings and ophthalmic shields, and consumer applications under brands like MedaGel, LumaGel Beauty, Kenkoderm, and Silly George.

NexGel manufactures hydrogel sheets in Langhorne, Pennsylvania, at an FDA-registered, cGMP facility. A joint venture, CG Converting and Packaging, LLC, in Granbury, Texas, handles final product converting, packaging, and fulfillment. The company is expanding its market presence in Europe and Canada, including a partnership with STADA and approval to sell SilverSeal in Canada.

NexGel's brand reputation is characterized by strong revenue growth and strategic expansion. The company experienced significant revenue increases in Q1 and Q2 2025, driven by consumer demand and new contract manufacturing agreements. The Silly George brand's growth and strategic partnerships with STADA and Cintas Corporation also contribute positively. Innovation efforts, such as the hydrogel trial for laser hair removal, further support its reputation. While stock underperformance exists, there are no explicit reports of negative events impacting the brand.

NexGel, Inc. has 24 institutional owners and shareholders, holding a total of 562,937 shares, representing 2.21% of the stock. Major institutional shareholders include Vanguard Group Inc., Morgan Stanley, Geode Capital Management, Llc, Renaissance Technologies Llc, and Susquehanna International Group, Llp. Insiders hold 20.55% of the stock and have sold more company stock ($15,940.00) than they have bought ($0.00) in the past three months.